Organogenesis Holdings Inc.
$2.48
The Read: Organogenesis shares have historically declined sharply despite meeting earnings estimates due to negative market reactions to full-year guidance, projected revenue declines from reimbursement risks, and disruption in the skin substitute market after Medicare policy changes.
Price
Overlays
Panel
ORGO
Hover to view data
No Data